search for




 

Analysis of Clinical Effects of Palivizumab for Children with Older Siblings
J. Kor. Soc. Health-syst. Pharm. 2018;35:400-408
Published online November 30, 2018;  https://doi.org/10.32429/jkshp.2018.35.4.002
© 2018 Korean Society of Health-System Pharmacists

Jin Yeo Kim, Ji Eun Park, Min Jae Jung, Jae Song Kim, Soo Hyun Kim and Eun Sun Son

Department of Pharmacy, Severance Hospital, Yon-sei University Health System, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea
Correspondence to: Eun Sun Son, Tel:02-2228-6888, E-mail:sespharm@yuhs.ac
Received February 8, 2018; Revised March 22, 2018; Accepted September 14, 2018.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background : Palivizumab is an intravenous monoclonal antibody which is used in the prevention of respiratory syncytial virus (RSV) infection. It is currently recommended for infants who are at high-risk for RSV infections due to preterm birth or other medical conditions such as congenital heart disease. Palivizumab is a humanized monoclonal antibody directed against an epitope in the antigenic site A of the protein F of RSV particles. Palivizumab is given once a month via intramuscular (IM) injection throughout the duration of the RSV season. Since palivizumab is known to have preventive effects against RSV infection for children with older siblings, the insurance coverage for palivizumab was expanded in October 2016.
Methods : The electronic medical records of children under 2 years old who have older siblings who visited or were admitted to the Severance Hospital from October 2015 to May 2016 and from October 2016 to May 2017 were reviewed retrospectively. The data were then divided into two groups depending on the pilivizumab administration.
Results : A total of 67 patients were enrolled in this study. The effectiveness in the reduction of hospitalization was statistically significant (p=0.009). Palivizumab decreased respiratory symptoms such as cough, rhinorrhea, and fever in patients with older siblings (p<0.05).
Conclusions : In this study, palivizumab administration was effective in preventing RSV infection in infants with older siblings. Expanding palivizumab-prophylaxis administration to infants with older siblings may be effective in the prevention of upper respiratory infections.
Keywords : Palivizumab, RSV (Respiratory Syncytial Virus), Siblings